[{"id":"a68faa2b-d426-44af-a80f-b0fc99a1c7cd","acronym":"NXP800-101","url":"https://clinicaltrials.gov/study/NCT05226507","created_at":"2023-04-14T16:03:28.481Z","updated_at":"2025-02-25T15:12:35.833Z","phase":"Phase 1","brief_title":"A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer","source_id_and_acronym":"NCT05226507 - NXP800-101","lead_sponsor":"Nuvectis Pharma, Inc.","biomarkers":" ARID1A • BRCA","pipe":" | ","alterations":" ARID1A mutation • BRCA mutation","tags":["ARID1A • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NXP800"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-13"},{"id":"b28bd860-d85f-4416-a7a1-e5a3d9f0f8a8","acronym":"MK-6482-030","url":"https://clinicaltrials.gov/study/NCT06234605","created_at":"2024-02-01T00:20:48.241Z","updated_at":"2025-02-25T16:11:25.934Z","phase":"Phase 1","brief_title":"A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma","source_id_and_acronym":"NCT06234605 - MK-6482-030","lead_sponsor":"HiberCell, Inc.","biomarkers":" VHL","pipe":" | ","alterations":" VHL mutation","tags":["VHL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Welireg (belzutifan) • HC-7366"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/29/2024","start_date":" 04/29/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-11-22"}]